|
|
||||||||
Division of Nuclear Medicine and Radiation Health Sciences, The Johns Hopkins Medical Institutions, Baltimore, Maryland
Correspondence: For reprints correspondence contact: Ursula Scheffel, Division of Nuclear Medicine and Radiation Health Sciences, The Johns Hopkins Medical Institutions, 615 North Wolfe St., Baltimore, MD 21205-2179.
ABSTRACT
A radioligand for imaging central serotonin (5-hydroxytryptamine; 5-HT) uptake sites by positron emission tomography (PET) has yet to be developed. Such a tracer would be useful for the study of normal and altered serotonergic neurotransmission as well as for the detection of serotonergic neurotoxicity. This paper describes the labeling of the highly potent serotonin (5-HT) uptake blocker, McN-5652-Z (trans-1,2,3,5,6,10ß-hexahydro-6-[4-(methylthio)phenyl]pyrrolo[2,1-a]-isoquinoline; racemic mixture), with 11C and the evaluation of this radiotracer in rodents with respect to its in vivo binding characteristics. In mouse brain, 11C-McN-5652-Z accumulated rapidly in regions with high densities of 5-HT uptake sites. The ratio between hypothalamus and cerebellum was 1.5:1 at 15 min and increased with time to 4.6:1 at 90 min after injection. The distribution of 11C-McN-5652 in rat brain at 60 min correlated well with regional concentrations of 5-HT uptake sites (r = 0.86). The specificity and selectivity of 11C-McN-5652 binding to the 5-HT transporter were tested by preinjecting blocking doses of known 5-HT, dopamine and norepinephrine uptake inhibitors, and a 5-HT2 receptor blocker before injection of the radiotracer. Preinjection of increasing doses of unlabeled McN-5652-Z inhibited 11C-McN 5652-Z binding in a dose-dependent fashion. These results suggest that the in vivo binding of the radiotracer was specific, selective for 5-HT uptake sites, saturable and that 11C-McN-5652-Z holds promise as a radiotracer for PET imaging of 5-HT uptake sites in the mammalian brain.
This article has been cited by other articles:
![]() |
M. Slifstein Revisiting an Old Issue: The Discrepancy Between Tissue Ratio-Derived Binding Parameters and Kinetic Modeling-Derived Parameters After a Bolus of the Serotonin Transporter Radioligand 123I-ADAM J. Nucl. Med., February 1, 2008; 49(2): 176 - 178. [Full Text] [PDF] |
||||
![]() |
A. B. Newberg, J. D. Amsterdam, N. Wintering, K. Ploessl, R. L. Swanson, J. Shults, and A. Alavi 123I-ADAM Binding to Serotonin Transporters in Patients with Major Depression and Healthy Controls: A Preliminary Study J. Nucl. Med., June 1, 2005; 46(6): 973 - 977. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Newberg, K. Plossl, P. D. Mozley, J. B. Stubbs, N. Wintering, M. Udeshi, A. Alavi, T. Kauppinen, and H. F. Kung Biodistribution and Imaging with 123I-ADAM: A Serotonin Transporter Imaging Agent J. Nucl. Med., May 1, 2004; 45(5): 834 - 841. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bolon Comparative and Correlative Neuroanatomy for the Toxicologic Pathologist Toxicol Pathol, January 1, 2000; 28(1): 6 - 27. [Abstract] [PDF] |
||||
![]() |
G. Pineyro and P. Blier Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |